MIM Software Inc. Receives CE Mark Approval for MAA SPECT/CT Dosimetry
CLEVELAND, Aug. 5, 2021 /PRNewswire/ --MIM Software Inc., a leading global provider of medical imaging software, announced today it has received CE Mark approval for MAA voxel-based SPECT/CT dosimetry through its MIM SurePlan LiverY90 product.
- CLEVELAND, Aug. 5, 2021 /PRNewswire/ --MIM Software Inc., a leading global provider of medical imaging software, announced today it has received CE Mark approval for MAA voxel-based SPECT/CT dosimetry through its MIM SurePlan LiverY90 product.
- The software allows physicians to quickly calculate the dose delivered by the microspheres to improve treatment decisions and patient care.
- "With this new dosimetry capability, interventional radiologists can efficiently conduct pre-treatment activity planning using formulas traditionally provided by microsphere manufacturers, as well as take advantage of MAA voxel-based dosimetry simulation," said Aaron Nelson, MD, Chief Medical Officer of MIM Software.
- MIM Software is used in 16 of the top 20 hospitals listed in the U.S. News & World Report Hospital Rankings & Ratings.